Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology

Chinese Journal of Cancer

Volumn 31, Issue 2, 2012, Pages 100-109

  Xue, Xue ^a   Liang, Xing Jie ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer nanotechnology; Drug efflux transporter; Multidrug resistance

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; SMALL INTERFERING RNA;

CANCER RESISTANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRUG TRANSPORT; GYNECOLOGIC CANCER; HUMAN; MULTIDRUG RESISTANCE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; P-GLYCOPROTEINS;

EID: 84857973669     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10326     Document Type: Review

References (71)

1. The World Cancer Report-the major findings. Cent Eur J Public Health, 2003,11:177-179.
2. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-gl ycoprotein) gene from multi drug-re sistant human cells. Cell, 1986,47:381-389.
3. Myers AM, Crivellone MD, Tzagoloff A. Assembly of the mitochondrial membrane system. MRP1 and MRP2, two yeastnuclear genes coding for mitochondrial ribosomal proteins. J Biol Chem, 1987,262:3388-3397.
4. Maliepaard M, van Gastelen MA, de Jong LA, et al. Over expression of the BCRP/MXR/ABCP gene in a topotecan- selected ovarian tumor cell line. Cancer Res, 1999,59:4559-4563.
5. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta, 2004,1644:229-249.
6. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun, 2005,331:868-880.
7. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 1992,255:459-462.
8. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist, 2003,8:411-424.
9. Szakacs G, Varadi A, Ozvegy-Laczka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-TO X). Drug Discov Today, 2008,13:379-393.
10. Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv, 2004,1:27-47
11. Zhang JT. Use of arrays to investigate the contribution of ATP- binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res, 2007,17: 311-323.
12. Gottesman MM, Fojo T, Bates SE. Multi drug resistance in cancer: role of ATP-de pendent transporters. Nat Rev Cancer, 2002,2: 48-58.
13. Wang Q, Wang JR, Wang HL, et al. Down-re gulation of P-gl ycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res, 2010,30: 3593-3598.
14. Shiraki N, Hamada A, Ohmura T, et al. Increase in doxorubicin cytotoxicity by inhibition of P-gl ycoprotein activity with lomerizine. Biol Pharm Bull, 2001,24: 555-557.
15. van Asperen J, van Tellingen O, Tijssen F, et al. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-gl ycoprotein. Br J Cancer, 1999,79: 108-113.
16. Pires MM, Emmert D, Hrycyna CA, et al. Inhibition of P-gl ycoprotein-m ediated paclitaxel resistance by reversibly linked quinine homo dimers. Mol Pharmacol, 2009,75:92-100.
17. Enokida H, Gotanda T, Oku S, et al. Reversal of P-glycoprotein- mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn J Cancer Res, 2002,93: 1037-1046.
18. Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol, 1974,83: 103-116.
19. See YP, Carlsen SA, Till JE, et al. Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta, 1974,373:242-252.
20. Hede S, Huilgol N. Nano: the new nemesis of cancer. J Cancer Res Ther, 2006,2:186-195.
21. Moghimi SM, Hunter AC, Murray JC. Nano medicine: current status and future prospects. FASEB J, 2005,19:311-330.
22. Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle, 2009,8:3480-3487.
23. Nie S, Xing Y, Kim GJ, et al. Nanotechnology applications in cancer. Annu Rev Biomed Eng, 2007,9:257-288.
24. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2003,2:347-360.
25. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti tumor agent smancs. Cancer Res, 1986,46:6387-6392.
26. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng, 1999,1:241-263.
27. Leroux JC. Injectable nano carriers for biodetoxification. Nat Nanotechnol, 2007,2:679-684.
28. Haley B, Frenkel E. Nano particles for drug delivery in cancer treatment. Urol Oncol, 2008,26:57-64.
29. Thierry B. Drug nanocarriers and functional nano particles: applications in cancer therapy. Curr Drug Deliv, 2009,6:391-403.
30. Alexis F, Pridgen EM, Langer R, et al. Nano particle technologies for cancer therapy. Handb Exp Pharmacol, 2010,197:55-86.
31. Constantinides PP, Wasan KM. Lipid formulation strategies foren hancing intestinal transport and absorption of P-gl ycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci, 2007,96:235-248.
32. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multi drug resistance in cancer. Nat Rev Drug Discov, 2006,5:219-234.
33. Dintaman JM, Silverman JA. Inhibition of P-g lycoprotein by D-al pha-to copheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res, 1999,16:1550-1556.
34. Batrakova EV, Li S, Vinogradov SV, et al. Mechanism of pluro nic effect on P-glycoprotein efflux system in blood-br ain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther, 2001,299:483-493.
35. Batrakova EV, Li S, Li Y, et al. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res, 2004, 21:2226-2233.
36. Hyafil F, Vergely C, Du Vignaud P, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res, 1993,53:4595-4602.
37. Witherspoon SM, Emerson DL, Kerr BM, et al. Flow cytometricassay of modulation of P-gl ycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res, 1996,2:7-12.
38. Wang Z, Li Y, Ahmad A, et al. Targeting mirnas involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat, 2010,13:109-118.
39. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm, 2009,367:195-203.
40. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res, 2009,15: 3770-3780.
41. Meng H, Liong M, Xia T, et al. Engineered design of meso porous silica nanoparticles to deliver doxorubicin and P-glycoprotein si RNA to overcome drug resistance in a cancer cell line. ACS Nano, 2010,4:4539-4550.
42. Jiang J, Yang SJ, Wang JC, et al. Sequential treatment of drug-re sistant tumors with RGD-m odified liposomes containing si RNA or doxorubicin. Eur J Pharm Biopharm, 2010,76:170-178.
43. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-re sistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol, 2009,27:643-651.
44. Walther W, Stein U, Lage H. Jet-in jection of short hairpin RNA- encoding vectors into tumor cells. Methods Mol Biol, 2010,629: 123-139.
45. Lu HL, Syu WJ, Nishiyama N, et al. Dendrimer phthalocyanine-encapsulated polymeric micelle-m ediated photochemicalinternalization extends the efficacy of photodynamic therapy and overcomes drug-re sistance in vivo. J Control Release, 2011,12, Epub ahead of print.
46. Patil Y, Sadhukha T, Ma L, et al. Nano particle-m ediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release, 2009,136: 21-29.
47. Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nano particle-m ediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials, 2010,31:358-365.
48. Volk LD, Flister MJ, Chihade D, et al. Synergy of nab- paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia, 2011,13: 327-338.
49. Khdair A, Handa H, Mao G, et al. Nanoparticle-m ediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur J Pharm Biopharm, 2009,71:214-222.
50. Khdair A, Chen D, Patil Y, et al. Nanoparticle-m ediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release, 141:137-144.
51. Chen K, Iribarren P, Hu J, et al. Activation of toll-lik e receptor 2 on microglia promotes cell uptake of alzheimer disease- associated amyloid beta peptide. J Biol Chem, 2006,281: 3651-3659.
52. Song XR, Zheng Y, He G, et al. Development of PLGA nano particles simultaneously loaded with vincristine and verapamil for treatment of hepato cellular carcinoma. J Pharm Sci, 2010,99:4874-4879.
53. Chen Y, Bathula SR, Li J, et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem, 2010,285:22639-22650.
54. van Vlerken LE, Duan Z, Little SR, et al. Augmentation of therapeutic efficacy in drug-re sistant tumor models using ceramide coadministration in temporal-co ntrolled polymer-bl end nanoparticle delivery systems. AAPS J, 2010,12:171-180.
55. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bo und-ra pamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther, 2010,9:963-975.
56. Lai BB, Chen BA, Cheng J, et al. Daunorubicin-lo added magnetic nanoparticles of Fe (3)O (4) greatly enhance the responses of multidrug-re sistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2009,17:345-351.
57. Ono C, Takao A, Atsumi R. Absorption, distribution, and excretion of DJ-92 7, a novel orally effective taxane, in mice, dogs, and monkeys. Biol Pharm Bull, 2004,27:345-351.
58. Shionoya M, Jimbo T, Kitagawa M, et al. DJ-92 7, a novel oral taxane, overcomes P-gl ycoprotein-m ediated multidrug resistance in vitro and in vivo. Cancer Sci, 2003,94:459-466.
59. Baas P, Szczesna A, Albert I, et al. Phase I/II study of a 3 weekly oral taxane (DJ-92 7) in patients with recurrent, advanced non-sm all cell lung cancer. J Thorac Oncol, 2008,3: 745-750.
60. Minderman H, Brooks TA, O'Loughlin KL, et al. Broad- spectrum modulation of ATP-bi nding cassette transport proteins by the taxane derivatives ortataxel (IDN-51 09, BAY 59-88 62) and tRA96023. Cancer Chemother Pharmacol, 2004,53:363-369.
61. Cassinelli G, Lanzi C, Supino R, et al. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-88 62) on hormone-re fractory prostate cancer. Clin Cancer Res, 2002,8:2647-2654.
62. Altstadt TJ, Fairchild CR, Golik J, et al. Synthesis and anti tumor activity of novel C-7 paclitaxel ethers: discovery of BMS-18 4476. J Med Chem, 2001,44:4577-4583.
63. Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-18 4476 as second-lin e in non-sm all-ce ll lung cancer. Ann Oncol, 2005,16:597-601.
64. Bilenker JH, Stevenson JP, Gallagher ML, et al. Phase I trial of the novel taxane BMS-18 4476 administered in combination with carboplatin every 21 days. Br J Cancer, 2004,91:213-218.
65. Kurata T, Shimada Y, Tamura T, et al. Phase I and pharmacokinetic study of a new taxoid, RPR5 109881A, given as a 1-ho ur intravenous infusion in patients with advanced solid tumors. J Clin Oncol, 2000,18:3164-3171.
66. Gelmon KA, Latreille J, Tolcher A, et al. Phase I dose-fin ding study of a new taxane, RPR 109881A, administered as a one- hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol, 2000,18:4098-4108.
67. Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-ho ur or a 3-ho ur infusion in patients with advanced solid tumors. Ann Oncol, 2002,13:1140-1150.
68. Miele E, Spinelli GP, Tomao F, et al. Albumin-bo und formulation of paclitaxel (Abraxane ABI-00 7) in the treatment of breast cancer. Int J Nanomedicine, 2009,4:99-105.
69. Moreno-Aspitia A, Perez EA. Nano particle albumin-bo und paclitaxel (ABI-00 7): a newer taxane alternative in breast cancer. Future Oncol, 2005,1:755-762.
70. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/ lonidamine delivery to treat multi-dr ug resistance in human breast and ovarian tumor cells. Mol Pharm, 2011,8:185-203.
71. Wang YZ, Huang B, Lv J, et al. Current status of nanotechnology applied in biomedicine. Acta Biophys Sin, 2009,25:168